Ro 90-7501 - CAS:293762-45-5

您当前的位置：

Ro 90-7501

目录号 : KM4915 CAS No. : 293762-45-5

Data Sheet 产品使用指南

Ro 90-7501 是一种淀粉样 β₄₂ (Aβ₄₂) 原纤维组装抑制剂，可降低 Aβ₄₂ 诱导的细胞毒性 (EC₅₀ 为 2 μM)。Ro 90-7501 抑制 ATM 磷酸化和 DNA 修复。RO 90-7501选择性增强 TLR3 和 RLR 配体诱导的 IFN-β 基因表达和抗病毒反应。Ro 90-7501 还以 TPR 依赖性方式抑制蛋白磷酸酶 5 (PP5)，并对宫颈癌细胞具有显着的放射增敏作用。

规格	价格	是否有货	数量
5mg		In-stock
10mg		In-stock
25mg		In-stock
50mg		In-stock
100mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Ginkgolide B In-stock
Isoginkgetin In-stock
Ginkgolic acid C17:1 In-stock
Ginkgolic Acid In-stock
Propargyl-PEG4-amine In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response. Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner. Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells.

体外研究

Ro 90-7501 significantly enhances radiosensitivity compared with control HeLa and ME-180 cells. Ro 90-7501 significantly increases apoptosis and impaired cell cycle after irradiation. Ro 90-7501 suppresses the phosphorylation of ATM and its downstream proteins, such as H2AX, Chk1, and Chk2, after irradiation.
RO 90-7501, itself affects neither IFN-β nor NFκB promoter activity, but significantly enhances poly I:C-induced IFN-β promoter activation and inhibits the activation of NFκB in a dose-dependent manner. Treatment of cells with RO 90-7501 significantly enhances the antiviral activity of poly I:C.

体内研究

Ro 90-7501 (5 μg/g; intraperitoneal injection; daily; for 21 days; female BALB/c nude mice) treatment significantly delays tumor growth and significantly decreases tumor volume.

Animal Model:	Female BALB/c nude mice (8-week-old) with HeLa cells under irradiation
Dosage:	5 μg/g
Administration:	Intraperitoneal injection; daily; for 21 days
Result:	Tumor growth was significantly delayed in the combination group. Tumor volume was also significantly decreased in the irradiation group.

分子式

C₂₀H₁₆N₆

分子量

340.38

CAS号

293762-45-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 41.67 mg/mL (122.42 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9379 mL	14.6895 mL	29.3789 mL
5 mM	0.5876 mL	2.9379 mL	5.8758 mL
10 mM	0.2938 mL	1.4689 mL	2.9379 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 2.08 mg/mL (6.11 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (6.11 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。